180 related articles for article (PubMed ID: 35328672)
1. A Histone Deacetylase (HDAC) Inhibitor with Pleiotropic In Vitro Anti-
Jublot D; Cavaillès P; Kamche S; Francisco D; Fontinha D; Prudêncio M; Guichou JF; Labesse G; Sereno D; Loeuillet C
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328672
[TBL] [Abstract][Full Text] [Related]
2. A potent HDAC inhibitor blocks Toxoplasma gondii tachyzoite growth and profoundly disrupts parasite gene expression.
Mouveaux T; Rotili D; Boissavy T; Roger E; Pierrot C; Mai A; Gissot M
Int J Antimicrob Agents; 2022 Mar; 59(3):106526. PubMed ID: 35041939
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics.
Araujo-Silva CA; De Souza W; Martins-Duarte ES; Vommaro RC
Int J Parasitol Drugs Drug Resist; 2021 Apr; 15():25-35. PubMed ID: 33360687
[TBL] [Abstract][Full Text] [Related]
4.
Zhang Y; Zhang Q; Li H; Cong H; Qu Y
Front Cell Infect Microbiol; 2022; 12():1002817. PubMed ID: 36171756
[TBL] [Abstract][Full Text] [Related]
5. Targeted Structure-Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo Site Inhibitors of Toxoplasma gondii and Plasmodium falciparum Cytochrome bc
McConnell EV; Bruzual I; Pou S; Winter R; Dodean RA; Smilkstein MJ; Krollenbrock A; Nilsen A; Zakharov LN; Riscoe MK; Doggett JS
ACS Infect Dis; 2018 Nov; 4(11):1574-1584. PubMed ID: 30117728
[TBL] [Abstract][Full Text] [Related]
6. Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds.
Maubon D; Bougdour A; Wong YS; Brenier-Pinchart MP; Curt A; Hakimi MA; Pelloux H
Antimicrob Agents Chemother; 2010 Nov; 54(11):4843-50. PubMed ID: 20713670
[TBL] [Abstract][Full Text] [Related]
7. Impaired chromatin remodelling at STAT1-regulated promoters leads to global unresponsiveness of Toxoplasma gondii-infected macrophages to IFN-γ.
Lang C; Hildebrandt A; Brand F; Opitz L; Dihazi H; Lüder CG
PLoS Pathog; 2012 Jan; 8(1):e1002483. PubMed ID: 22275866
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor MS-275 augments expression of a subset of IFN-γ-regulated genes in Toxoplasma gondii-infected macrophages but does not improve parasite control.
Sumpf K; Nast R; Downie B; Salinas G; Lüder CGK
Exp Parasitol; 2017 Sep; 180():45-54. PubMed ID: 28189488
[TBL] [Abstract][Full Text] [Related]
9. Previous Infection with Plasmodium berghei Confers Resistance to Toxoplasma gondii Infection in Mice.
Lee DH; Chu KB; Kang HJ; Lee SH; Quan FS
Korean J Parasitol; 2019 Apr; 57(2):93-99. PubMed ID: 31104401
[TBL] [Abstract][Full Text] [Related]
10. Hydroxamate-based compounds are potent inhibitors of
Boissavy T; Rotili D; Mouveaux T; Roger E; Aliouat EM; Pierrot C; Valente S; Mai A; Gissot M
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0066123. PubMed ID: 37850734
[TBL] [Abstract][Full Text] [Related]
11. Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.
Chua MJ; Arnold MS; Xu W; Lancelot J; Lamotte S; Späth GF; Prina E; Pierce RJ; Fairlie DP; Skinner-Adams TS; Andrews KT
Int J Parasitol Drugs Drug Resist; 2017 Apr; 7(1):42-50. PubMed ID: 28107750
[TBL] [Abstract][Full Text] [Related]
12. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii.
Araujo FG; Huskinson J; Remington JS
Antimicrob Agents Chemother; 1991 Feb; 35(2):293-9. PubMed ID: 2024964
[TBL] [Abstract][Full Text] [Related]
13. Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites.
Bougdour A; Maubon D; Baldacci P; Ortet P; Bastien O; Bouillon A; Barale JC; Pelloux H; Ménard R; Hakimi MA
J Exp Med; 2009 Apr; 206(4):953-66. PubMed ID: 19349466
[TBL] [Abstract][Full Text] [Related]
14. Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.
Strobl JS; Cassell M; Mitchell SM; Reilly CM; Lindsay DS
J Parasitol; 2007 Jun; 93(3):694-700. PubMed ID: 17626366
[TBL] [Abstract][Full Text] [Related]
15. Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites.
Engel JA; Jones AJ; Avery VM; Sumanadasa SD; Ng SS; Fairlie DP; Skinner-Adams T; Andrews KT
Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):117-26. PubMed ID: 26199860
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor AR-42 and achiral analogues kill malaria parasites in vitro and in mice.
Chua MJ; Tng J; Hesping E; Fisher GM; Goodman CD; Skinner-Adams T; Do D; Lucke AJ; Reid RC; Fairlie DP; Andrews KT
Int J Parasitol Drugs Drug Resist; 2021 Dec; 17():118-127. PubMed ID: 34560571
[TBL] [Abstract][Full Text] [Related]
17. Targeted Phenotypic Screening in
Subramanian G; Belekar MA; Shukla A; Tong JX; Sinha A; Chu TTT; Kulkarni AS; Preiser PR; Reddy DS; Tan KSW; Shanmugam D; Chandramohanadas R
mSphere; 2018; 3(1):. PubMed ID: 29359192
[TBL] [Abstract][Full Text] [Related]
18. Toxoplasma histone acetylation remodelers as novel drug targets.
Vanagas L; Jeffers V; Bogado SS; Dalmasso MC; Sullivan WJ; Angel SO
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1189-201. PubMed ID: 23199404
[TBL] [Abstract][Full Text] [Related]
19. NADPH Oxidase and Guanylate Binding Protein 5 Restrict Survival of Avirulent Type III Strains of Toxoplasma gondii in Naive Macrophages.
Matta SK; Patten K; Wang Q; Kim BH; MacMicking JD; Sibley LD
mBio; 2018 Aug; 9(4):. PubMed ID: 30154263
[TBL] [Abstract][Full Text] [Related]
20. Metacytofilin Is a Potent Therapeutic Drug Candidate for Toxoplasmosis.
Leesombun A; Iijima M; Umeda K; Kondoh D; Pagmadulam B; Abdou AM; Suzuki Y; Ohba SI; Isshiki K; Kimura T; Kubota Y; Sawa R; Nihei CI; Nishikawa Y
J Infect Dis; 2020 Feb; 221(5):766-774. PubMed ID: 31573038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
